Clinical trial
Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable…
NCT00089362 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00089362 |
|---|---|
| Title | Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors |
| Official title | Phase 1 Study of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG, NSC #707545) in Patients With Solid Tumors. |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Male Breast Cancer, Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Basal Cell Carcinoma of the Lip, Recurrent Breast Cancer, Recurrent Colon Cancer, Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity, Recurrent Gastric Cancer, Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity, Recurrent Lymphoepithelioma of the Nasopharynx, Recurrent Lymphoepithelioma of the Oropharynx and 67 more |
| Intervention type | Drug, Other |
| Interventions | alvespimycin hydrochloride, laboratory biomarker analysis, pharmacological study |
| Enrollment | 30 |
| Start date | Jul 1, 2004 |
| Primary completion | Jan 1, 2008 |
| First posted | Aug 5, 2004 |
| Last update posted | Apr 10, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: